Mandate

Vinge has advised Pareto Securities AB and Swedbank AB (publ) in connection with a bond issue with a framework amount of up to MSEK 700

December 18, 2017 Banking and Finance

Vinge has advised Pareto Securities AB and Swedbank AB (publ) in connection with a bond issue with a framework amount of up to MSEK 700 senior unsecured floating rate bonds, issued by Offentliga Hus i Norden AB (publ) (”Offentliga Hus”) on 15 December 2017.

Pareto Securities AB and Swedbank AB (publ) have acted as arrangers and Swedbank AB (publ) also acted as issuing agent. The bonds have a tenor of three and a half years and a floating interest rate of three-months STIBOR plus a margin of 7.00 per cent.
 
The proceeds from the bond issue will be applied towards financing property acquisitions and other general corporate purposes. Offentliga Hus intends to apply for the bonds to be listed on Nasdaq Stockholm.
 
Vinges team consisted inter alia of Louise Brorsson Salomon, Lionardo Ojeda and Sara Osman.

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026